Work

Oncolytic Virotherapy for the Treatment of Malignant Glioma

Year: 2017

Type: review

Source: Neurotherapeutics

DOI: 10.1007/s13311-017-0516-0

Authors: Paul M. Foreman, Gregory K. Friedman, Kevin A. Cassady, James M. Markert

Institutions: University of Alabama at Birmingham, Nationwide Children's Hospital

Language: English

Topic: Virus-based gene therapy research

Subfield: Genetics

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: U.S. Department of Defense, Rally Foundation, University of Alabama at Birmingham, University of Alabama, U.S. Food and Drug Administration, U.S. Public Health Service, National Cancer Institute, National Institute of Neurological Disorders and Stroke, Kaul Pediatric Research Institute

Awards: Engineered HSV For Treatment of Malignant Glioma, Cytochrome C Oxidase: Biomarker In Newly Diagnosed Glioblastoma Multiforme, G2800195642, A Phase 1 Study of M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma., CONTEMPORARY THERAPEUTICS FOR ANAPLASTIC GLIOMAS, G4119534169, G4370540960, Research Training Program in Surgical Oncology, INTRAVENTRICULAR DELIVERY OF ENGINEERED ONCOLYTIC HERPES SIMPLEX VIROTHERAPY TO TREAT LOCALIZED AND METASTATIC PEDIATRIC BRAIN TUMORS, Molecular Therapeutics for Anaplastic Gliomas

OpenAlex ID: W2593529561

FWCI: 2.01

Cites: 80

Cited by: 130

Related to: 10